Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
FBLG Stock Chart & Stats
$0.39
-$0.09(-3.98%)
At close: 4:00 PM EST
$0.39
-$0.09(-3.98%)
Day’s Range― - ―
52-Week Range$0.22 - $1.53
Previous CloseN/A
Volume56.64K
Average Volume (3M)978.93K
Market Cap
$26.31M
Enterprise Value$14.02M
Total Cash (Recent Filing)$4.89M
Total Debt (Recent Filing)$2.41M
Price to Earnings (P/E)―
Beta0.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding67,594,720
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.14
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$2.75Price Target Upside605.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ValidationInterim and final results from the Phase 1/2 diabetic foot ulcer trial for CYWC628 can provide direct clinical proof of efficacy for the fibroblast platform and reduce development risk across other indications.
Financing And Balance SheetCapital raise and full repayment of outstanding debt strengthens the balance sheet and enables continued funding of clinical programs and manufacturing scale-up without immediate dilutive financing.
Regulatory Pathway ExpansionFiling of the IND for the allogeneic fibroblast spheroid candidate CYPS317 for moderate-to-severe psoriasis establishes a regulatory pathway that could broaden clinical opportunities into dermatology and immune-related diseases.
Bears Say
Manufacturing Completion RiskUncertainty about manufacturing completion for the trial therapy raises the possibility of production delays that could postpone dosing and regulatory progress.
Patient Enrollment RiskVague enrollment plans for the diabetic foot ulcer study increase the risk of slow patient recruitment, which could delay study readouts and exacerbate execution risk.
Trial Timeline UncertaintyUnclear start and procedural details for the diabetic foot ulcer trial create uncertainty around the timing of clinical milestones and potential data-driven stock moves.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.22 and its highest was $1.53 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $26.31M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were FibroBiologics, Inc.’s earnings last quarter?
Currently, no data Available
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 67,594,720 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$2.75
▲(605.13% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―
Ownership Overview
9.14% Insiders
1.99% Mutual Funds
1.47% Other Institutional Investors
85.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---